Johanna Friedl-Naderer is CCO at Dyne Therapeutics, Inc. (DYN). They have made 1 open-market trade across 1 company since 2023, most recently 2026-09-08.
CIK 0001915598
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| DYN | SELL · 10b5-1 | 2026-09-04 | 2026-09-08 | $23.42 | $25K | -11.4% | -15.3% | — |
| DYN | SELL · 10b5-1 | 2026-08-13 | 2026-08-17 | $26.28 | $6K | +0.0% | -33.6% | — |
| DYN | SELL · 10b5-1 | 2026-06-16 | 2026-06-17 | $18.33 | $3K | +9.0% | +16.5% | -12.0% |
| DYN | SELL · 10b5-1 | 2026-05-13 | 2026-05-14 | $18.36 | $4K | +1.7% | +5.2% | +46.7% |
| DYN | SELL · 10b5-1 | 2026-03-05 | 2026-03-06 | $14.90 | $2K | +19.8% | +20.2% | +20.5% |
| DYN | SELL · 10b5-1 | 2025-12-05 | 2025-12-05 | $20.72 | $3K | -12.5% | -15.6% | -29.6% |
| DYN | SELL · 10b5-1 | 2025-09-04 | 2025-09-08 | $13.29 | $14K | +5.0% | +9.8% | +67.4% |
| DYN | SELL · 10b5-1 | 2025-06-05 | 2025-06-06 | $13.35 | $2K | -29.1% | -46.2% | -12.9% |
| DYN | SELL · 10b5-1 | 2025-03-13 | 2025-03-13 | $12.12 | $2K | -5.2% | -37.9% | +21.1% |
| VIR | SELL | 2023-03-03 | 2023-03-07 | $22.82 | $34K | +4.1% | +5.1% | +17.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.